PACS Group PACS announced that the subsidiaries of the company have entered definitive agreements to acquire the operations of 32 skilled nursing facilities across Florida. The facilities, which will be leased from subsidiaries of existing REIT landlord Omega Healthcare Investors, have a combined 4,049 licensed skilled nursing beds and are integrated into local healthcare networks across the state. The transaction is expected to establish a statewide network for PACS and expand its presence in a high-growth post-acute care market.
Per Jason Murray, chairman and CEO of PACS, the entry into Florida marks an important expansion opportunity for PACS, with the state offering strong demographic demand and significant potential for growth in post-acute care. The expansion aligns with the company’s long-term strategy of entering attractive markets while strengthening care delivery. PACS plans to support local teams, build on the facilities’ existing operational strengths and bring its culture, values and commitment to localized care to the communities it serves.
PACS Stock Trend Following the News
Shares of PACS have lost 3.3% since the announcement on Thursday. Year to date, the stock has gained 10.7% compared with the industry’s 2.8% growth and the S&P 500’s 12.1% return.
The planned Florida expansion is a positive development for PACS as it significantly increases the company’s scale and establishes a presence in a new state. Adding 32 facilities and more than 4,000 licensed beds should expand PACS’s addressable market, strengthen its post-acute care network and provide opportunities to leverage its operating model across Florida.
PACS currently has a market capitalization of $6.73 billion.
Image Source: Zacks Investment Research
More on the News
The Florida acquisition will further expand PACS’ operations in the South, complementing its existing footprint of 25 facilities in Texas, 27 in South Carolina, 12 in Tennessee and seven in Kentucky. The transaction is anticipated to close in the fourth quarter of 2026, subject to customary closing conditions and contingencies.
PACS president and COO Josh Jergensen said that the company is looking forward to working with the acquired facilities and their local leadership teams, leveraging its locally led, centrally supported operating model as the integration process begins following the expected closing. The transaction aligns with PACS’s disciplined growth strategy, focusing on opportunities where strong local leadership can benefit from the company’s operating model while maintaining high-quality care for residents and communities.
Industry Prospects Favoring the Market
According to data provided by Precedence Research, the U.S. post-acute care market is predicted to be valued at $532.48 billion in 2026 and is expected to witness a CAGR of 4.9% through 2035.
Factors like the increasing demand for quality care and speedy recovery, rising geriatric population in the country, mounting cases of chronic diseases and growing demand for home-based services post-hospitalization are boosting the market’s growth.
Other News
PACS provided an update on its previously announced acquisition of Eduro Healthcare’s 34 skilled nursing facilities. Following the closing of 20 facilities on Aug. 1, PACS completed the acquisition of 11 additional facilities on Sep. 3, bringing the total number of completed acquisitions to 31 of the 34 facilities, representing 3,633 skilled nursing beds. The remaining three facilities are pending closing, subject to customary conditions. The completed transactions have increased PACS’ affiliated buildings to 355 and expanded its presence into New Mexico, North Dakota and South Dakota.
PACS Group, Inc. Price
PACS Group, Inc. price | PACS Group, Inc. Quote
PACS’s Zacks Rank & Other Key Picks
Currently, PACS carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks from the broader medical space are Veracyte VCYT, Globus Medical GMED and West Pharmaceutical WST.
Veracyte, currently flaunting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%. You can see the complete list of today’s Zacks #1 Rank stocks here.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 41.8%.
Globus Medical, currently carrying a Zacks Rank #2, reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 27.9%.
West Pharmaceutical, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
PACS Group, Inc. (PACS): Free Stock Analysis Report
West Pharmaceutical Services, Inc. (WST): Free Stock Analysis Report
Globus Medical, Inc. (GMED): Free Stock Analysis Report
Veracyte, Inc. (VCYT): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).